All currency values in $ millions unless otherwise noted
| Income Statement | TTM | DEC 2025 5:1 split | DEC 2024 |
|---|---|---|---|
| Revenues | |||
| Revenue | $0 | $0 | – |
| General & Administrative | $19 | $14 | $5 |
| Research & Development | $55 | $49 | $17 |
| Provision for Doubtful Accounts | – | $0 | $0 |
| Total Operating Expenses | $74 | $63 | $23 |
| Operating Income | -$74 | -$63 | -$23 |
| Non-Operating | |||
| Net Interest Expense | $4 | $5 | $2 |
| Other Non-Operating Income (Expense) | $4 | $5 | $2 |
| Income Tax Expense | – | $0 | $0 |
| Net Income | |||
| Net Income | -$70 | -$58 | -$21 |
| Per Share Data | |||
| Revenue Per Share | $0.00 | $0.00 | – |
| EPS (Basic) | -$3.21 | -$2.93 | -$5.15 |
| EPS (Diluted) | -$3.21 | -$2.93 | -$5.15 |
| Weighted Avg Shares (Basic) | 21.8M | 19.6M | 4.0M |
| Weighted Avg Shares (Diluted) | 21.8M | 19.6M | 4.0M |
| Shares Outstanding | 21.8M | 19.6M | 4.0M |
Aardvark Therapeutics (AARD) financials: revenue, profit and margins
Aardvark Therapeutics (AARD) generated about $0.00 in revenue and -$70 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Aardvark Therapeutics's (AARD) revenue?+
Aardvark Therapeutics generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Aardvark Therapeutics profitable?+
Aardvark Therapeutics reported about -$70 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with AARD
Held by ETFs
AARD is in 4 US ETFs. The largest of them, with AARD's weight in each:
Spot a number that looks wrong? Check it in AARD's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AARD
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.